drugset / Trial / NCT03916640

A Trial to Assess a Co-formulation of an Insulin Analog and Pramlintide in Subjects With Type 1 Diabetes Mellitus

NCT03916640

Phase 1 Completed 24 enrolled Adocia
RandomizedCrossoverTriple-blindTreatment

Summary

This trial is a monocentric, randomised, double-blind, active comparator, controlled, 3-period cross-over trial.

Timeline

Start
2019-01-04
Primary completion
2019-03-01
Completion
2019-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ADO09 Unknown Subcutaneous
Comparator Insulin Protein / enzyme biologic Subcutaneous
Comparator Insulin Lispro Protein / enzyme biologic Subcutaneous
Comparator Pramlintide Peptide Subcutaneous